Heart failure is a relatively common complication in older women with breast cancer, but the risk is even higher in those patients treated with adjuvant trastuzumab (Herceptin©), Yale School of Medicine researchers report in the current issue of the Journal of the American College of Cardiology.
The researchers conducted this study because older women who are at higher risk of decreased heart function, were often excluded from randomized clinical trials of trastuzumab, which is used to treat breast tumors that over-express human epidermal growth factor receptor-2 (HER-2). Past clinical trials in younger, healthier women showed improved survival, but also increased heart complications linked to trastuzumab, especially when combined with a frequently used therapy called anthracycline chemotherapy.
"We observed an even higher risk of heart failure or cardiomyopathy after trastuzumab therapy than those in past clinical trials," said lead author Jersey Chen, M.D., assistant professor of cardiology at Yale University School of Medicine and a member of the Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale.
The Yale COPPER team examined the association between the use of adjuvant trastuzumab and anthracycline therapy and heart failure and cardiomyopathy, the most serious cardiotoxic complications, in 45,536 female Medicare beneficiaries with early-stage breast cancer. The use of trastuzumab has increased over time from 2.6% of the women who received any adjuvant therapy in 2000 to 22.6% in 2007.
The team found that compared with patients who received no adjuvant chemotherapy or trastuzumab; use of trastuzumab was associated with a 14% higher adjusted incidence rate for heart failure or cardiomyopathy over three years. Patients who received both trastuzumab and anthracycline had a 23.8% higher rate, and those treated with anthracycline chemotherapy alone had a 2.1% higher rate of heart failure or cardiomyopathy events over three years.
"Further study is needed to fully understand the benefits and risks of trastuzamab when they are used in the real-world population," said Cary Gross, senior author of the study and director of the COPPER Center.
Yale University: http://www.yale.edu
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Fans of "Flappy Bird" may find its successor even more frustrating, but just as addictive
Even just the word Ebola is kind of terrifying. Why? Hollywood has a lot to do with it. But Ebola outbreaks also have all the ingredients for what one psychologist calls the "dread factor."
If we want to understand whats happening in the brain when people hear voices, we first need to understand what happens during ordinary inner speechHearing voices: whats your experience when reading?
Seals and sea lions may have brought a form of tuberculosis to the Americas, centuries before the Spanish did so
More people with non-fatal conditions are travelling to assisted dying clinics in Switzerland
We’re all born to adore ourselves, but not all of us grow up
Rumours of dubious treatments are spreading on social media in West Africa, while fishy Ebola treatments are being peddled to anxious US citizens
The type of Ebola erupting in West Africa is closely related to one found 2,500 miles away — the distance between Boston and San Francisco. How did the virus spread so far without anyone noticing?
The tendency of Clostridium novyi to kill mammal cells has been used to shrink tumours in dogs and people, so the bacteria could help fight some cancers
The Burns Collection consists of human cadavers from the early 1800s that were anatomically dissected and preserved to teach anatomy and surgery to medical students. For the first time this portion of the collection is on display to the public as a part of traveling exhibit "Mummies of the World: The Exhibition."